De-escalating chemotherapy for stage I-II gastric neuroendocrine carcinoma? A real-world competing risk analysis

• Published in: World journal of surgical oncology Vol. 21; no. 1; p. 142
• Main Authors: Du, Danwei, Xie, Yangyang, Li, Xiaowen, Ni, Zhongkai, Shi, Jinbo, Huang, Hai
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 06.05.2023; BioMed Central; BMC
• Subjects: Adjuvant treatment; Age; Calibration; Cancer; Cancer therapies; Carcinoma, Neuroendocrine - drug therapy; Care and treatment; Chemotherapy; Chemotherapy, Adjuvant; Competing risk analyses; Databases, Factual; Diagnosis; Epidemiology; Gastric cancer; Gender; Health aspects; Health risk assessment; Hospitals; Humans; Marital status; Medical prognosis; Medicine, Chinese; Methods; Multivariate analysis; Neoplasms; Neuroendocrine tumors; Nomogram; Nomograms; Pathology; Patients; Regression analysis; Risk analysis; Risk assessment; SEER Program; Stomach cancer; Stomach Neoplasms - drug therapy; Surgery; Surveillance; Survival; Survival analysis; Tumor staging; Japan; Competing risk analyses; Chemotherapy; SEER Program; Gastric cancer; Nomogram
• ISSN: 1477-7819; 1477-7819
• DOI: 10.1186/s12957-023-03029-2

The role of adjuvant chemotherapy in gastric neuroendocrine neoplasms (GNEC) has not been well clarified yet. The study was designed to investigate the potential effect of adjuvant chemotherapy in stage I-II GNEC patients and construct a predictive nomogram. Stage I-II GNEC patients were included in the Surveillance, Epidemiology, and End Results (SEER) database and divided into chemotherapy and no-chemotherapy groups. We used Kaplan-Meier survival analyses, propensity score matching (PSM), and competing risk analyses. The predictive nomogram was then built and validated. Four hundred four patients with stage I-II GNEC were enrolled from the SEER database while 28 patients from Hangzhou TCM Hospital were identified as the external validation cohort. After PSM, similar 5-year cancer-specific survival was observed in two groups. The outcomes of competing risk analysis indicated a similar 5-year cumulative incidence of cancer-specific death (CSD) between the two cohorts (35.4% vs. 31.4%, p = 0.731). And there was no significant relation between chemotherapy and CSD in the multivariate competing risks regression analysis (HR, 0.79; 95% CI, 0.48-1.31; p = 0.36). Furthermore, based on the variables from the multivariate analysis, a competing event nomogram was created to assess the 1-, 3-, and 5-year risks of CSD. The 1-, 3-, and 5-year area under the receiver operating characteristic curve (AUC) values were 0.770, 0.759, and 0.671 in the training cohort, 0.809, 0.782, and 0.735 in the internal validation cohort, 0.786, 0.856, and 0.770 in the external validation cohort. Furthermore, calibration curves revealed that the expected and actual probabilities of CSD were relatively consistent. Stage I-II GNEC patients could not benefit from adjuvant chemotherapy after surgery. De-escalation of chemotherapy should be considered for stage I-II GNEC patients. The proposed nomogram exhibited excellent prediction ability.